RxDoctor Payments Data

Elyse Rubenstein, MD

Rheumatology · Santa Monica, CANPI 1508895095

Payments from drug & device makers

$15,346in general payments, 2019–2025

Across 771 payments — averaging $19.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$3K
  • AbbVie$3K
  • Johnson & Johnson$2K
  • GSK$1K
  • Novartis$1K
  • Pfizer$774
  • plus $4K from 24 others

What the payments were for

  • Food & beverage$15,296100%
  • Education$500%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,346 in reported general payments places this provider in the 70th percentile of 808 rheumatology providers in California.

See all rheumatology providers in California

Medicare billing

Part B allowed, 2024
$315,615
Medicare patients
458
Services billed
2,976

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab60$763,092
Enbrel SureclickEtanercept42$356,666
ProliaDenosumab162$276,031
EnbrelEtanercept31$271,005
Teriparatide52$123,728
Orencia ClickjectAbatacept20$105,787
ForteoTeriparatide21$87,249
KevzaraSarilumab14$72,505
Evenity (2 Syringes)Romosozumab-Aqqg20$49,089
TymlosAbaloparatide12$32,056
Hydroxychloroquine Sulfate299$11,522
MyrbetriqMirabegron15$11,023
OxycontinOxycodone Hcl13$9,540
MethotrexateMethotrexate Sodium290$6,469
Duloxetine Hcl226$5,309

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenProlia, Enbrel, Evenity (2 Syringes)$3,367$596,124213 claims
Alvogen IncTeriparatide$226$123,72852 claims
Lilly USA, LLCForteo$595$87,24921 claims
SanofiKevzara$181$72,50514 claims
Radius Health, Inc.Tymlos$230$32,05612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 808 rheumatology providers in California.

Other rheumatology in Santa Monica

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →